Inhibikase Therapeutics (IKT) Total Debt (2020 - 2025)
Inhibikase Therapeutics (IKT) posted quarterly Total Debt of $37944.0 for Q2 2025, down 75.07% year-over-year from $152224.0 in Q2 2024, and down 49.25% quarter-over-quarter from $74772.0 in Q1 2025.
Inhibikase Therapeutics (IKT) Total Debt (2020 - 2025) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Total Debt for 6 consecutive years, with $37944.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Total Debt fell 75.07% year-over-year to $37944.0; the TTM figure through Jun 2025 stood at $37944.0 (down 75.07% YoY), while the FY2024 annual figure was $110517.0, down 79.22% from the prior year.
- Total Debt retreated to $37944.0 in Q2 2025 per IKT's latest filing, from $74772.0 in the prior quarter.
- Across five years, Total Debt topped out at $1.2 million in Q1 2021 and bottomed at $37944.0 in Q2 2025.
- Historically, Total Debt has averaged $245133.9 across 5 years, with a median of $147966.0 in 2023.
- Annual changes were most pronounced in 2023 — Total Debt jumped 264.71% — and 2024, when it slumped 79.22%.
- Inhibikase Therapeutics' Total Debt stood at $248911.0 in 2021, then sank by 41.41% to $145836.0 in 2022, then surged by 264.71% to $531879.0 in 2023, then plunged by 79.22% to $110517.0 in 2024, then plunged by 65.67% to $37944.0 in 2025.
- Business Quant data shows IKT's Total Debt at $37944.0 in Q2 2025, $74772.0 in Q1 2025, and $110517.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 37,944.00 |
| Mar 31, 2025 | 74,772.00 |
| Dec 31, 2024 | 110,517.00 |
| Sep 30, 2024 | 145,210.00 |
| Jun 30, 2024 | 152,224.00 |
| Mar 31, 2024 | 151,159.00 |
| Dec 31, 2023 | 531,879.00 |
| Sep 30, 2023 | 149,030.00 |
| Jun 30, 2023 | 147,966.00 |
| Mar 31, 2023 | 146,901.00 |
| Dec 31, 2022 | 145,836.00 |
| Sep 30, 2022 | 142,048.00 |
| Sep 30, 2021 | 248,911.00 |
| Jun 30, 2021 | 248,911.00 |
| Mar 31, 2021 | 1.24 Mn |
| Dec 31, 2020 | 276,461.00 |